Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
Type:
Application
Filed:
January 30, 2019
Publication date:
May 30, 2019
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Inventors:
Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
Abstract: The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
Type:
Application
Filed:
May 17, 2017
Publication date:
May 23, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Sarah C. Garrett-Thomson, Steven C. Almo, Ronald D. Seidel III
Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
Type:
Grant
Filed:
August 25, 2016
Date of Patent:
May 21, 2019
Assignees:
Albert Einstein College of Medicine, The Governing Council of the University of Toronto
Inventors:
Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
Type:
Grant
Filed:
September 20, 2018
Date of Patent:
May 21, 2019
Assignees:
Albert Einstein College of Medicine, Victoria Link Limited
Inventors:
Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.
Type:
Grant
Filed:
November 23, 2010
Date of Patent:
May 14, 2019
Assignees:
The Johns Hopkins University, Albert Einstein College of Medicine, Inc.
Inventors:
Kieren A. Marr, Janet F. Staab, Marta Feldmesser
Abstract: Methods are provided for producing differentiated cells from stem cells, including producing hepatocytes. Compositions thereof are also provided, as are methods of treating a liver disorder.
Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
Type:
Grant
Filed:
April 24, 2015
Date of Patent:
May 7, 2019
Assignee:
Albert Einstein College of Medicine
Inventors:
Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
Type:
Application
Filed:
May 9, 2017
Publication date:
May 2, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
Abstract: Methods are disclosed for treating cancers using antibodies and antibody fragments that inhibit the activity of Vascular cell adhesion molecule 1 (Vcam1) and/or Macrophage erythroblast attacher (Maea).
Type:
Application
Filed:
November 26, 2018
Publication date:
March 14, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
PAUL S. FRENETTE, SANDRA PINHO, QIAOZHI WEI
Abstract: Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2.
Type:
Grant
Filed:
March 12, 2018
Date of Patent:
March 5, 2019
Assignee:
Albert Einstein College of Medicine, Inc.
Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
Type:
Grant
Filed:
January 10, 2018
Date of Patent:
January 29, 2019
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
Inventors:
Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
Abstract: Methods and systems for obtaining inhibitors of Nuclear receptor SET Domain containing protein 2 (NSD2) are disclosed where the methods involve designing compounds that resemble the NSD2 transition state.
Type:
Application
Filed:
December 14, 2016
Publication date:
January 24, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
Type:
Application
Filed:
September 20, 2018
Publication date:
January 17, 2019
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., VICTORIA LINK LIMITED
Inventors:
Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kifl9 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.
Type:
Application
Filed:
September 27, 2018
Publication date:
January 17, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin:total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.
Type:
Application
Filed:
July 24, 2018
Publication date:
January 10, 2019
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., KING'S COLLEGE LONDON
Inventors:
John Condeelis, Tony Tsz-Cheong Ng, Gregory Weitsman
Abstract: A novel optogenetic system, including constructs and methods, is provided based on the interaction of Rhodopseudomonas palustris BphP1 and Rhodopseudomonas palustris PpsR2 or a non-dimerizing variant thereof.
Type:
Application
Filed:
September 29, 2016
Publication date:
December 6, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Vladislav V. Verkhusha, Andrii A. Kaberniuk, Anton A. Shemetov
Abstract: Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins. The invention provides methods of treating or preventing arthritis, such as osteoarthritis, in a subject in need thereof comprising administering to the subject a formulation or composition comprising carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins in an amount effective to treat or prevent arthritis.
Type:
Application
Filed:
November 2, 2015
Publication date:
November 22, 2018
Applicants:
Montefiore Medical Center, Albert Einstein College of Medicine, Inc.
Inventors:
Hui B. Sun, Daniel J. Leong, Neil J. Corbelli, David M. Hirsh, John A. Hardin, Karen E. Sperling, Sun Jin Kim, David C. Spray, Chandan Guha, Marwa Choudhury